The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II Trial of Gemcitabine (G) and Cisplatin (C) in Non-Small Cell Lung Cancer with Poor Prognosis with Emphasis on Hematological Toxicity.
 
Chigusa Morizane
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Bristol-Myers Squibb; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Junki Mizusawa
Honoraria - Chugai Pharma
 
Hiroshi Katayama
Honoraria - Johnson & Johnson
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Eisai
Research Funding - AstraZeneca; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Merck Serono; MSD; NanoCarrier; Ono Pharmaceutical; Shire; Taiho Pharmaceutical
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Eisai; Kyowa Hakko Kirin; NanoCarrier; Novartis; Shire
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Masato Ozaka
Honoraria - Bayer; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kazuya Sugimori
No Relationships to Disclose
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - Merck Serono (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobumasa Mizuno
Honoraria - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Taiho Pharmaceutical
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Keiji Sano
No Relationships to Disclose
 
Kazutoshi Tobimatsu
No Relationships to Disclose
 
Kei Yane
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai
 
Naohiro Sata
No Relationships to Disclose
 
Seigo Yukisawa
No Relationships to Disclose
 
Hiroshi Ishii
Honoraria - Astellas Pharma; Chugai Pharma; Eisai; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)